Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Director | June 10, 2026 | June 12, 2026 |
| Parabilis Medicines, Inc.PBLS · Entity 3933 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09 | Direct | 9,250 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F3: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. |
| Common StockSEC Table I · non-derivative | Direct | 148,391 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 148,391 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. |
| Common StockSEC Table I · non-derivative | IndirectGrantor and Trustee | 42,166 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 42,166 F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. F2: Consists of 7,900 shares held by The Klausner Family Revocable Trust of May 8, 2014, 12,275 shares held by The Ariella Klausner Delaware Trust, 9,716 shares held by The Eli Klausner Delaware Trust and 12,275 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein |
Filing footnotes · ownership attribution and instrument terms
F1: On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.
F2: Consists of 7,900 shares held by The Klausner Family Revocable Trust of May 8, 2014, 12,275 shares held by The Ariella Klausner Delaware Trust, 9,716 shares held by The Eli Klausner Delaware Trust and 12,275 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein
F3: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Parabilis Medicines, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2036-06-08 | Direct | 20,215 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 20,215 · Balance 20,215 F1: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 07, 2018
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-07 · Gift · Disposed 23,250 · Balance 705,525 F1: Represents a bona fide gift of common stock; thus, there is no price associated with this transaction. Row 2 · 2018-03-05 · Other · Disposed 705,525 · Balance 0 F2: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.00 · Expires 2025-06-11 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.40 · Expires 2026-06-16 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2027-06-15 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-05 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a bona fide gift of common stock; thus, there is no price associated with this transaction.
F2: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F4: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 20:21 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 9,250 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001591178-26-000002 · form4-06122026_080656.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:43 UTC | Parabilis Medicines, Inc. PBLS · Entity 3933 | GrantStock Option (Right to Buy) · Derivative | 20,215 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001193125-26-267747 · ownership.xml · derivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,215 Underlying: Common Stock · 20,215 shares Expires 2036-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 22:50 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-25-013723 · form4-05192025_100514.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-05-14 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 00:07 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | PurchaseCommon Stock | 158,000 | $0.60 | $94,942.20 |
DisclosureSEC source: 0001415889-25-008540 · form4-03192025_120347.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grantor and Trustee Disclosed balance after: 843,365 F1 · price: The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.62, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range. F2 · ownership.nature: Consists of 158,000 shares held by The Klausner Family Revocable Trust of May 8, 2014, 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust and 245,515 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 20:15 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 130,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001415889-24-017176 · form4-06172024_080654.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-06-13 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| September 08, 2023 Filed Sep 8, 2023 20:30 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-048788 · doc4.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-09-07 F2 · security: On September 6, 2023, to align with benchmarking data, the issuers Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Persons total 2023 grants with the updated policy. F3 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Persons service as a director ends at such annual meeting due to the Reporting Persons failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:23 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 58,020 | $2.28 | $132,285.60 |
DisclosureSEC source: 0001209191-23-046267 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Grantor Disclosed balance after: 930,880 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.275 to $2.285, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: Consists of 245,515 shares held by The Ariella Klausner Delaware Trust, 194,335 shares held by The Eli Klausner Delaware Trust, 245,515 shares held by The Isaac Klausner Delaware Trust, and 245,515 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. Raymond James Trust Services of Delaware is the trustee of each of the trusts. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 20:45 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001209191-23-038439 · doc4.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-15 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 22:14 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | SaleCommon Stock | 11,100 | $6.40 | $71,041.11 |
DisclosureSEC source: 0001209191-22-051379 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Grantor Disclosed balance after: 988,900 F1 · ownership.nature: Consists of 250,000 shares held by The Ariella Klausner Delaware Trust, 238,900 shares held by The Eli Klausner Delaware Trust, 250,000 shares held by The Isaac Klausner Delaware Trust, and 250,000 shares held by The Olivia Klausner Delaware Trust. The Reporting Person is a grantor of each of the trusts and disclaims beneficial ownership of all shares held by the trusts except to any pecuniary interest therein. Raymond James Trust Services of Delaware is the trustee of each of the trusts. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 65,000 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001209191-22-035825 · doc4.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-07 F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person providing continuous service through such date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:36 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,765,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042798 · doc4.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Lyell Investors, LLC Disclosed balance after: 0 Underlying: Common Stock · 3,765,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F1 · derivative.exercise_date: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F1 · derivative.expiration_date: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F2 · ownership.nature: The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 21:36 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | ConversionCommon Stock | 3,765,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-042798 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Lyell Investors, LLC Disclosed balance after: 3,765,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Issuer's Series A Convertible Preferred Stock converted into Common Stock on a 1-for-1 basis and had no expiration date. F2 · ownership.nature: The Reporting Person is a manager of Lyell Investors, LLC (Lyell Investors) and may be deemed to share the power to direct the disposition and vote of the shares held by Lyell Investors. The Reporting Person disclaims beneficial ownership of all shares held by Lyell Investors except to any pecuniary interest therein Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:21 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $63.71 Strike: $23.29 | $764,520.00 |
DisclosureSEC source: 0001209191-18-017815 · doc4.xml · derivative · entry 5 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-06-15 F2 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:21 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $44.60 Strike: $42.40 | $535,200.00 |
DisclosureSEC source: 0001209191-18-017815 · doc4.xml · derivative · entry 4 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2026-06-16 F2 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:21 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 12,000 | $27.00 Strike: $60.00 | $324,000.00 |
DisclosureSEC source: 0001209191-18-017815 · doc4.xml · derivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2025-06-11 F2 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · price: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. F4 · derivative.exercise_date: In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:21 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | OtherCommon Stock | 705,525 | $87.00 | $61,380,675.00 |
DisclosureSEC source: 0001209191-18-017815 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F3 · date: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Read SEC document |
| February 07, 2018 Filed Mar 7, 2018 18:21 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GiftCommon Stock | 23,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017815 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,525 F1 · price: Represents a bona fide gift of common stock; thus, there is no price associated with this transaction. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:05 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 918 | $49.37 | $45,321.29 |
DisclosureSEC source: 0001209191-18-003055 · doc4.xml · nonDerivative · entry 5 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,775 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.34 to $49.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:05 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 4,846 | $48.95 | $237,222.85 |
DisclosureSEC source: 0001209191-18-003055 · doc4.xml · nonDerivative · entry 4 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,693 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.34 to $49.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:05 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 5,011 | $47.80 | $239,537.83 |
DisclosureSEC source: 0001209191-18-003055 · doc4.xml · nonDerivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,539 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $47.29 to $48.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 08, 2018 Filed Jan 9, 2018 21:05 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 1,949 | $46.85 | $91,309.68 |
DisclosureSEC source: 0001209191-18-003055 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,550 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $46.29 to $47.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2018 Filed Jan 9, 2018 21:05 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003055 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,499 Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 16:58 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 3,141 | $45.16 | $141,849.13 |
DisclosureSEC source: 0001209191-17-067084 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 741,251 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.12 to $45.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 21, 2017 Filed Dec 22, 2017 16:58 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 32,859 | $44.72 | $1,469,507.05 |
DisclosureSEC source: 0001209191-17-067084 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 744,392 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.12 to $45.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 05, 2017 Filed Oct 6, 2017 19:31 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 266 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056351 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777,251 Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 19:29 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 1,337 | $43.83 | $58,604.72 |
DisclosureSEC source: 0001209191-17-052159 · doc4.xml · nonDerivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 776,985 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $43.61 to $44.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 19:29 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 5,214 | $42.76 | $222,939.69 |
DisclosureSEC source: 0001209191-17-052159 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,322 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.48 to $43.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 07, 2017 Filed Sep 8, 2017 19:29 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 5,449 | $42.27 | $230,321.06 |
DisclosureSEC source: 0001209191-17-052159 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 783,536 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.48 to $42.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 07, 2017 Filed Aug 9, 2017 19:43 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 12,000 | $30.34 | $364,090.80 |
DisclosureSEC source: 0001209191-17-048356 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,985 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.04 to $30.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2017 Filed Jul 7, 2017 19:49 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 400 | $30.00 | $11,999.00 |
DisclosureSEC source: 0001209191-17-044461 · doc4.xml · nonDerivative · entry 3 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,985 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $29.97 to $30.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 07, 2017 Filed Jul 7, 2017 19:49 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 23,600 | $29.38 | $693,320.80 |
DisclosureSEC source: 0001209191-17-044461 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801,385 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.97 to $29.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 19:49 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 380 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044461 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,985 Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 16:36 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $23.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040847 · doc4.xml · derivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the option become vested and exercisable on the earlier of (i) the date of the 2018 Annual Meeting of Stockholders and (ii) the first anniversary of the grant date, in either event, subject to the director continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through such date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 19:37 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 8,768 | $24.24 | $212,528.43 |
DisclosureSEC source: 0001209191-17-039017 · doc4.xml · nonDerivative · entry 2 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824,605 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.73 to $24.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 19:37 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 15,232 | $23.23 | $353,833.27 |
DisclosureSEC source: 0001209191-17-039017 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,373 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.73 to $23.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 05, 2017 Filed Apr 6, 2017 16:50 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026105 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,605 Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 17:06 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 591 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-002965 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848,091 Read SEC document |
| October 05, 2016 Filed Oct 17, 2016 20:44 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 401 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146110 · doc4.xml · nonDerivative · entry 1 Klausner Richard · CIK 0001591178 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.